OTCMKTS:OPHLF Ono Pharmaceutical Q3 2026 Earnings Report $16.11 0.00 (0.00%) As of 09/25/2026 ProfileEarnings HistoryForecast Ono Pharmaceutical EPS ResultsActual EPS$0.40Consensus EPS $0.29Beat/MissBeat by +$0.11One Year Ago EPSN/AOno Pharmaceutical Revenue ResultsActual Revenue$892.70 millionExpected Revenue$727.58 millionBeat/MissBeat by +$165.12 millionYoY Revenue GrowthN/AOno Pharmaceutical Announcement DetailsQuarterQ3 2026Date2/2/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsOno Pharmaceutical's next earnings date is estimated for Thursday, October 29, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Ono Pharmaceutical Earnings HeadlinesOno Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?September 24 at 8:58 AM | finance.yahoo.comContrasting Silo Pharma (NASDAQ:SILO) and Ono Pharmaceutical (OTCMKTS:OPHLF)September 22, 2026 | americanbankingnews.comThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan.September 26 at 1:00 AM | Base Camp Trading (Ad)Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological DiseasesSeptember 1, 2026 | businesswire.comOno Pharma’s New Cancer Trial Adds Early-Stage Upside—and Risk—for OPHLF InvestorsAugust 26, 2026 | tipranks.comOno Pharma Halts Early Lymphoma Trial, Raising Fresh Questions for InvestorsJuly 29, 2026 | tipranks.comSee More Ono Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ono Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ono Pharmaceutical and other key companies, straight to your email. Email Address About Ono PharmaceuticalOno Pharmaceutical (OTCMKTS:OPHLF) Co., Ltd. is a Japanese research-driven pharmaceutical company headquartered in Osaka. The company discovers, develops, manufactures and markets prescription medicines, with a focus on oncology, immunology, neurology and other specialty-care areas. Its activities include both internally developed products and collaborations with pharmaceutical and biotechnology companies worldwide. Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used to treat multiple types of cancer. The company’s portfolio also includes medicines for other therapeutic areas, such as diabetes, Parkinson’s disease and gastrointestinal conditions. Product availability and commercial rights vary by country and may be managed through licensing or co-development arrangements. Ono traces its origins to 1717, when it began as a pharmaceutical wholesaler in Osaka, and later transitioned toward pharmaceutical manufacturing and research. Today, it conducts research and development in Japan and works with partners to serve patients in markets around the world. The company is listed in Japan, and its shares also trade in the United States over the counter under the symbol OPHLF.View Ono Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
